MRD testing after stomach cancer surgery
Part of Cancer, Digestive system clinical trials.
This study looks at whether a blood test for leftover cancer cells (called MRD) after stomach cancer surgery can help guide treatment. It is for people with a certain type of stomach cancer that has spread to nearby tissues but not to distant organs, and who are having surgery as their first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of stomach cancer (adenocarcinoma, mucinous adenocarcinoma, or signet ring cell carcinoma).
- Your tumor is stage T4 (has spread to nearby tissues) but has not spread to distant organs, and you are scheduled for surgery to remove it.
- You are between 18 and 75 years old.
- You are physically active and able to care for yourself (ECOG score 0 or 1).
- You have not had chemotherapy or radiation before surgery, and you and your family prefer surgery first.
- Your blood counts and liver/kidney function are within normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks a simple blood test to look for tiny traces of cancer DNA after stomach cancer surgery. It aims to see if this test can catch any cancer coming back early, so you can get treatment sooner.
This trial is looking at whether giving extra treatment after surgery for stomach cancer can help lower the chance of it coming back. It is for people who had a specific kind of chemotherapy and immunotherapy before surgery and then had their stomach removed.
This trial checks “MRD” (tiny leftover cancer signals after surgery) to help decide the best additional treatment for early-stage breast cancer. It may help tailor therapy so you get the most useful medicines while avoiding unnecessary treatment.
This study checks if a blood test can find leftover cancer DNA after stomach cancer surgery. It helps doctors know if more treatment is needed.
This study uses a simple blood test (called MRD) after surgery to see if any tiny bits of cancer DNA are left. It helps doctors decide whether extra chemotherapy is needed or if it can be safely skipped, and it may reduce unnecessary side effects.
This trial tests whether using a special blood test (MRD) to guide chemotherapy after pancreatic cancer surgery can improve outcomes. It is for people who have had their cancer completely removed and are ready for standard follow-up therapy.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.